NuScale Power Surges 1.54% on Strategic Update Ranks 166th in $700M Volume

NuScale Power (SMR) closed on October 3, 2025, with a 1.54% increase in share price, marking a modest but notable gain amid a broader market session. The stock's trading volume reached $700 million, securing its position as the 166th most actively traded security on the day. This performance followed a strategic update regarding its advanced reactor technology roadmap, which emphasized regulatory milestones and potential cost reductions in modular construction phases.

Recent developments in the small modular reactor (SMR) sector highlighted NuScale’s competitive positioning as it announced a revised timeline for its first commercial plant deployment. The company outlined a phased approach to scale production, aligning with recent industry trends toward accelerated decarbonization projects. Analysts noted that the update addressed key investor concerns about project delays and capital efficiency, potentially stabilizing market sentiment in the near term.

Internal operational adjustments were also disclosed, including a restructuring of supply chain partnerships to reduce reliance on single-source vendors. This move aims to mitigate risks associated with global component shortages and align with the company’s long-term sustainability goals. While no direct financial figures were released, the strategic clarity provided has been interpreted as a positive signal for operational resilience in a capital-intensive industry.

To run this back-test rigorously I need to pin down (or work around) a few practical details: 1. Stock universe • Do you want “all U.S. common stocks” (NYSE + NASDAQ + AMEX), or a narrower list (e.g., S&P 1500 constituents, Russell 3000, etc.)? • ADRs, ETFs and penny stocks – should they be excluded? 2. Execution convention • The usual implementation of a “1-day hold” is: buy at today’s close, sell at tomorrow’s close. • Is that what you intend, or would you prefer buy at tomorrow’s open → sell at tomorrow’s close? 3. Frictional costs • Should we include estimated commissions and slippage? If yes, please specify the round-trip cost (e.g. 5 bp per side). 4. Data scale / platform limitation • Our one-click back-testing engine is designed for single-ticker or event studies, so a true 500-stock daily-rebalanced portfolio has to be handled with a custom multi-asset script outside the built-in tool chain. • I can either: a) build that custom script and share summarized results (will take more time), or b) approximate the idea with a readily-available index that captures “high-liquidity large-cap names” (e.g., equal-weight of the top-volume names rebalanced monthly) using the built-in tools. Please let me know your preferences for the four items above. After that I can proceed with the most appropriate workflow (either a custom run or a tool-based approximation).